Cleary, M. Et Al. 2019. ICV-administered tralesinidase alfa (BMN 250 NAGLU-IGF2) is well-tolerated and reduces heparan sulfate accumulation in the CNS of subjects with Sanfilippo syndrome type B (MPS IIIB). 15th Annual Research Meeting of the WORLDSymposium(TM) , (Florida, United States Of America).

Cleary, M., Muschol, N., Luz Couce, M., Harmatz, P., Lee, J., Lin, S., ... OKUR, İ.(2019). ICV-administered tralesinidase alfa (BMN 250 NAGLU-IGF2) is well-tolerated and reduces heparan sulfate accumulation in the CNS of subjects with Sanfilippo syndrome type B (MPS IIIB) . 15th Annual Research Meeting of the WORLDSymposium(TM), Florida, United States Of America

Cleary, Maureen Et Al. "ICV-administered tralesinidase alfa (BMN 250 NAGLU-IGF2) is well-tolerated and reduces heparan sulfate accumulation in the CNS of subjects with Sanfilippo syndrome type B (MPS IIIB)," 15th Annual Research Meeting of the WORLDSymposium(TM), Florida, United States Of America, 2019

Cleary, Maureen Et Al. "ICV-administered tralesinidase alfa (BMN 250 NAGLU-IGF2) is well-tolerated and reduces heparan sulfate accumulation in the CNS of subjects with Sanfilippo syndrome type B (MPS IIIB)." 15th Annual Research Meeting of the WORLDSymposium(TM) , Florida, United States Of America, 2019

Cleary, M. Et Al. (2019) . "ICV-administered tralesinidase alfa (BMN 250 NAGLU-IGF2) is well-tolerated and reduces heparan sulfate accumulation in the CNS of subjects with Sanfilippo syndrome type B (MPS IIIB)." 15th Annual Research Meeting of the WORLDSymposium(TM) , Florida, United States Of America.

@conferencepaper{conferencepaper, author={Maureen Cleary Et Al. }, title={ICV-administered tralesinidase alfa (BMN 250 NAGLU-IGF2) is well-tolerated and reduces heparan sulfate accumulation in the CNS of subjects with Sanfilippo syndrome type B (MPS IIIB)}, congress name={15th Annual Research Meeting of the WORLDSymposium(TM)}, city={Florida}, country={United States Of America}, year={2019}}